Cipher Pharmaceuticals Inc. (CPHRF)

Market Cap	252.69M +2.7%
Revenue (ttm)	49.49M -1.1%
Net Income	34.38M +98.0%
EPS	1.31 +97.2%
Shares Out	n/a
PE Ratio	7.57
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	18,110
Open	10.26
Previous Close	9.55
Day's Range	9.94 - 10.26
52-Week Range	9.27 - 15.00
Beta	0.25
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 12, 2026

About Cipher Pharmaceuticals

Cipher Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada. It offers Epuris (isotretinoin), an oral retinoid for the treatment of severe nodular and/or inflammatory acne, acne conglobate, and recalcitrant acne; Actikerall, a topical solution for the treatment of slightly palpable and/or moderately thick hyperkeratotic actinic keratosis (Grade I/II) of the face, forehead, and balding scalp; Vaniqa, a topical cream for the slowing of the growth of unwanted facial hair in women; Durela, an opioid analgesic for the manage...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2000
• Employees: 5
• Stock Exchange: OTCMKTS
• Ticker Symbol: CPHRF

Financial Performance

In 2025, Cipher Pharmaceuticals's revenue was $50.45 million, an increase of 51.22% compared to the previous year's $33.36 million. Earnings were $27.33 million, an increase of 136.72%.

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Nov 14, 2026

Data Sources Report a data error